1. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369–2379.
2. Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018;67:1024–1032.
5. Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion 2017;95:22–28.
6. Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016;164:337–340.
8. Lagier JC, Armougom F, Million M, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012;18:1185–1193.
16. Liu Y, Lin Z, Lin Y, et al.
Streptococcus and
Prevotella are associated with the prognosis of oesophageal squamous cell carcinoma. J Med Microbiol 2018;67:1058–1068.
17. Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to
Helicobacter pylori status. ISME J 2011;5:574–579.
19. Kim EJ, Baik GH. Review on gastric mucosal microbiota profiling differences in patients with chronic gastritis, intestinal metaplasia, and gastric cancer. Korean J Gastroenterol 2014;64:390–393.
21. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018;67:226–236.
22. Eun CS, Kim BK, Han DS, et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 2014;19:407–416.
23. Li TH, Qin Y, Sham PC, Lau KS, Chu KM, Leung WK. Alterations in gastric microbiota after
H. pylori eradication and in different histological stages of gastric carcinogenesis. Sci Rep 2017;7:44935.
24. Park JS, Park JE, Oh BS, et al. Trend in the eradication rates of
Helicobacter pylori infection over the last 10 years in West Gyeonggi-do, Korea: a single center experience. Korean J Gastroenterol 2017;70:232–238.
25. Lu M, Yu S, Deng J, et al. Efficacy of probiotic supplementation therapy for
Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One 2016;11:e0163743.
26. Kim JW. The effects of probiotics on the treatment of
Helicobacter pylori eradication. Korean J
Helicobacter Up Gastrointest Res 2016;16:129–133.
27. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by
Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077–1086.
28. Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of Lactobacillus-supplemented triple therapy for
Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr 2019;178:7–16.
29. Wen J, Peng P, Chen P, et al. Probiotics in 14-day triple therapy for Asian pediatric patients with
Helicobacter pylori infection: a network meta-analysis. Oncotarget 2017;8:96409–96418.
30. Feng JR, Wang F, Qiu X, et al. Efficacy and safety of probiotic-supplemented triple therapy for eradication of
Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol 2017;73:1199–1208.
31. Lau CS, Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of
Helicobacter pylori : a meta-analysis. Infect Drug Resist 2016;9:275–289; eCollection 2016.
32. McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for
Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J 2016;4:546–561.
33. Lu C, Sang J, He H, et al. Probiotic supplementation does not improve eradication rate of
Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep 2016;6:23522.
34. Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate
Helicobacter pylori : a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015;8:6530–6543; eCollection 2015.
35. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in
Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol 2015;21:4345–4357.
36. Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for
Helicobacter pylori infection: a metaanalysis. Exp Ther Med 2015;9:707–716.
37. Zhu R, Chen K, Zheng YY, et al. Meta-analysis of the efficacy of probiotics in
Helicobacter pylori eradication therapy. World J Gastroenterol 2014;20:18013–18021.
38. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on
Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One 2014;9:e111030.
40. Ohtsu T, Takagi A, Uemura N, et al. The ameliorating effect of lactobacillus gasseri OLL2716 on functional dyspepsia in
Helicobacter pylori-uninfected individuals: a randomized controlled study. Digestion 2017;96:92–102.
42. Urita Y, Goto M, Watanabe T, et al. Continuous consumption of fermented milk containing
Bifidobacterium bifidum YIT 10347 improves gastrointestinal and psychological symptoms in patients with functional gastrointestinal disorders. Biosci Microbiota Food Health 2015;34:37–44.
43. Gomi A, Yamaji K, Watanabe O, et al. Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: a double-blind, randomized, placebo-controlled study. J Dairy Sci 2018;101:4830–4841.
44. Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a
Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 2009;9:85.
45. Ianiro G, Pizzoferrato M, Franceschi F, Tarullo A, Luisi T, Gasbarrini G. Effect of an extra-virgin olive oil enriched with probiotics or antioxidants on functional dyspepsia: a pilot study. Eur Rev Med Pharmacol Sci 2013;17:2085–2090.
46. El Aidy S, van den Bogert B, Kleerebezem M. The small intestine microbiota, nutritional modulation and relevance for health. Curr Opin Biotechnol 2015;32:14–20.
48. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333–341.
49. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol 1996;40:553–560.
50. Watanabe T, Higuchi K, Kobata A, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008;57:181–187.
51. Watanabe T, Nishio H, Tanigawa T, et al. Probiotic
Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009;297:G506–G513.
53. Montalto M, Gallo A, Curigliano V, et al. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 2010;32:209–214.